SWM
GALT icon

SeaCrest Wealth Management’s Galectin Therapeutics GALT Stock Holding History

SeaCrest Wealth Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,900
Closed -$10K – 1009
2019
Q1 		$10K Hold
1,900
– – ﹤0.01% 1522
2018
Q4 		$7K Hold
1,900
– – ﹤0.01% 1592
2018
Q3 		$11K Sell
1,900
-1,100
-37% -$6.05K ﹤0.01% 1601
2018
Q2 		$19K Buy
+3,000
New +$14.6K ﹤0.01% 1379

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SeaCrest Wealth Management's GALT Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Galectin Therapeutics (GALT) in Q2 2019, closing a stake of 1,900 shares — an estimated $10K sold.

SeaCrest Wealth Management first reported a position in GALT in Q2 2018 and held it in 4 quarters. The position peaked at $19K in Q2 2018. 76 funds tracked by Wall St. Rank hold GALT as of Q2 2019.

  • SeaCrest Wealth Management reported no remaining Galectin Therapeutics position as of Q2 2019 after selling out during the quarter.
  • SeaCrest Wealth Management sold 1,900 Galectin Therapeutics shares in Q2 2019, an estimated $10K.
  • SeaCrest Wealth Management first reported a position in Galectin Therapeutics in Q2 2018 and held it in 4 quarters.
  • SeaCrest Wealth Management's Galectin Therapeutics position peaked at $19K in Q2 2018.
  • 76 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.